Vaxcyte Inc. Common Stock vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while YieldMax Universe Fund of Option Income ETFs trades at $7.33 (market cap $365.95M). The key difference: Vaxcyte Inc. Common Stock is far larger — about 28.7× YieldMax Universe Fund of Option Income ETFs's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and YieldMax Universe Fund of Option Income ETFs for 57 Days on average.
| PCVX | YMAX | |
|---|---|---|
Market Cap | $10.51B | $365.95M |
Volume | 2,644,694 | 1,000,945 |
Sector | Health | Income / Options Overlay |
52-Week High | $73.82 | $12.60 |
52-Week Low | $40.32 | $7.27 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $9.14B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YMAX trades at $7.61 with minimal daily movement (+0.13%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The fund maintains a high distribution policy with weekly dividends, but faces concerns about NAV erosion and sustainability. Recent portfolio adjustments aim to address performance issues while maintaining the ~40%+ annualized yield.
The outlook remains cautious due to structural concerns about distribution sustainability and NAV erosion. While the high yield attracts income investors, the fund's reverse split potential and stacked fee structure present significant risks. Analyst sentiment is mixed, with some questioning the long-term viability of the current distribution model amid persistent principal decline.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →